A Systematic Comparison of Market Access and Reimbursement Pathways for Diagnostic Tests in Germany, United Kingdom and the United States

Abstract

The number of eligible patients for each drug (141 -214,000) tends to correlate with the negotiated rebate. ConClusions: An additional benefit is necessary for a reimbursement beyond the reference group price. Despite the small number of observations it might be concluded, that the reimbursed price inversely correlates with disease incidence. The highest rebate on reimbursement price resulted from the decision of the arbitration board.